Schwartz Investment Counsel’s Vertex Pharmaceuticals VRTX Stock Holding History

Schwartz Investment Counsel’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$497K	Hold	1,000	–	–	0.02%	118
2026 Q1	$447K	Hold	1,000	–	–	0.02%	116
2025 Q4	$453K	Hold	1,000	–	–	0.02%	120
2025 Q3	$392K	Hold	1,000	–	–	0.01%	119
2025 Q2	$445K	Hold	1,000	–	–	0.01%	109
2025 Q1	$485K	Hold	1,000	–	–	0.02%	111
2024 Q4	$403K	Hold	1,000	–	–	0.01%	115
2024 Q3	$465K	Hold	1,000	–	–	0.02%	115
2024 Q2	$469K	Hold	1,000	–	–	0.02%	116
2024 Q1	$418K	Hold	1,000	–	–	0.02%	126
2023 Q4	$407K	Hold	1,000	–	–	0.02%	122
2023 Q3	$348K	Sell	1,000 -1,000	-50%	-$350K	0.01%	125
2023 Q2	$704K	Hold	2,000	–	–	0.03%	112
2023 Q1	$630K	Hold	2,000	–	–	0.03%	116
2022 Q4	$578K	Hold	2,000	–	–	0.03%	113
2022 Q3	$579K	Hold	2,000	–	–	0.03%	108
2022 Q2	$564K	Sell	2,000 -250	-11%	-$66.9K	0.03%	108
2022 Q1	$587K	Hold	2,250	–	–	0.02%	113
2021 Q4	$494K	Buy	2,250 +550	+32%	+$107K	0.02%	116
2021 Q3	$308K	Buy	1,700 +600	+55%	+$117K	0.01%	122
2021 Q2	$222K	Hold	1,100	–	–	0.01%	130
2021 Q1	$236K	Buy	+1,100	New	+$242K	0.01%	125

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Schwartz Investment Counsel's VRTX Position: Q2 2026 in Review

Schwartz Investment Counsel held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 1,000 shares worth $497K. The position accounts for 0.02% of the portfolio, ranked #118.

Schwartz Investment Counsel first reported a position in VRTX in Q1 2021 and has held it in 22 quarters since. The position peaked at $704K in Q2 2023. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Schwartz Investment Counsel held 1,000 shares of Vertex Pharmaceuticals worth $497K as of Q2 2026.
Schwartz Investment Counsel left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.02% of Schwartz Investment Counsel's portfolio in Q2 2026, its #118 holding.
Schwartz Investment Counsel first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
Schwartz Investment Counsel's Vertex Pharmaceuticals position peaked at $704K in Q2 2023.
1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Schwartz Investment Counsel's 13F filing for Q2 2026, filed 27 Jul 2026.